Introduction：Basic information about CAS 95522-45-5|Colestilan, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Colestilan |
|---|
| CAS Number | 95522-45-5 | Molecular Weight | 174.62800 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C7H11ClN2O | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 2-(chloromethyl)oxirane,2-methyl-1H-imidazole |
|---|
| Synonym | More Synonyms |
|---|
Colestilan BiologicalActivity
| Description | Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research[1][2]. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Metabolic Disease |
|---|
| In Vitro | Colestilan (MCI-196) decreases cholesterol levels by bile acid adsorption through the gastrointestinal tract[2]. Colestilan (1 g) binds 2.52 mmol of phosphate at 2–4 mM phosphate concentration and pH7.2 in vitro[2]. |
|---|
| In Vivo | Colestilan (MCI-196) (0.125 or 0.5 g content per 15 g of the feed; p.o.; 14 days) decreases blood phosphate and urinary phosphorus excretion in rats[3]. Colestilan is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks[1]. Animal Model: 6-week old Wistar male rats[3] Dosage: 0.125 or 0.5 g content per 15 g of the feed Administration: Oral in feed, 14 days Result: Dose dependently decreased blood phosphate and urinary phosphate excretion. |
|---|
| References | [1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010 Feb;25(2):574-81. [2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant. 2005 Feb;20(2):424-30. [3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960. |
|---|
Chemical & Physical Properties
| Molecular Formula | C7H11ClN2O |
|---|
| Molecular Weight | 174.62800 |
|---|
| Exact Mass | 174.05600 |
|---|
| PSA | 41.21000 |
|---|
| LogP | 1.34210 |
|---|
| InChIKey | DEMLYXMVPJAVFU-UHFFFAOYSA-N |
|---|
| SMILES | Cc1ncc[nH]1.ClCC1CO1 |
|---|
Synonyms
| Colestilan |
| Epichlorohydrin-2-methylimidazole copolymer |
| Colestimide |
| MCI 196 |
| Cholebine |
